Bisphosphonates in cancer therapy

Current Opinion in Oncology

Volumn 14, Issue 6, 2002, Pages 609-615

  Green, Jonathan R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DEXAMETHASONE; ETIDRONIC ACID; IBANDRONIC ACID; MEVALONIC ACID; MINODRONIC ACID; NITROGEN; PACLITAXEL; PAMIDRONIC ACID; RISEDRONIC ACID; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOCHEMISTRY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER INVASION; CELL ADHESION; CELL FUNCTION; DOSE RESPONSE; EXTRACELLULAR MATRIX; IN VITRO STUDY; IN VIVO STUDY; MICROENVIRONMENT; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; TUMOR CELL LINE; ANIMAL; BONE TUMOR; CLINICAL TRIAL; DISEASE MODEL; HUMAN; IMMUNOLOGY; METASTASIS; MOUSE; MULTIPLE MYELOMA; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTEIN PROCESSING;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; BONE RESORPTION; CLINICAL TRIALS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MULTIPLE MYELOMA; NEOPLASM METASTASIS; NEOPLASMS; OSTEOCLASTS; PROTEIN ISOPRENYLATION;

EID: 0036856052     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200211000-00004     Document Type: Review

References (65)

1. Fleisch H: Development of bisphosphonates. Breast Cancer Res 2002, 4:30-34.
2. Lipton A, Small E, Saad F, et al.: The new bisphosphonate, ZOMETA® (zoledronic acid) decreases skeletal complications in both lyric and blastic lesions: A comparison to pamidronate. Cancer Invest 2001, 20(suppl 12):45-47.
3. Rosen L, Gordon D, Tchekmedyian S, et al.: Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors. Proc Am Soc Clin Oncol 2002, 21:295a.
4. Rogers MJ, Gordon S, Benford HL, et al.: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978.
5. Dunford JE, Thompson K, Coxon FP, et al.: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther 2001, 296:235-242. A seminal study with a wide range of N-BPs showing a clear correlation among inhibition of farnesyl diphosphate synthase in vitro, inhibition of protein prenylation in cell-free extracts and in purified osteoclasts in vitro, and inhibition of bone resorption in vivo.
6. Alakangas A, Selander K, Mulari M, et al.: Alendronate disturbs vesicular trafticking in osteoclasts. Calcif Tissue Int 2002, 70:40-47. The changes induced by N-BPs in osteoclasts include accumulation of tartrate-resistant acid phosphatase and electron-dense tubular vesicles, impairment of intracellular vesicle transport, and disruption of the sealing zone and ruffled border, followed later by apoptosis.
7. Fisher JE, Rodan GA, Reszka AA: In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141:4793-4796.
8. Mathov I, Plotkin LI, Sgarlata CL, et al.: Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J Bone Miner Res 2001, 16:2050-2056.
9. Reinholz GG, Getz B, Pederson L, et al.: Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001-6007.
10. Benford HL, McGowan NWA, Helfrich MH, et al.: Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001, 28:465-473. An in vitro study showing that N-BPs produce the classic features of apoptosis in rabbit and human osteoclasts: characteristic morphologic changes, loss of mitochondrial membrane potential, and activation of caspase-3-like proteases. Bisphosphonate-induced apoptosis was suppressed by the caspase inhibitors zVAD-fmk and SB-281277 and could be mimicked by GGTI-298, a specific inhibitor of protein geranylgeranylation.
11. Clohisy DR, O'Keefe PF, Ramnaraine ML: Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice. J Orthop Res 2001, 19:554-558.
12. Van Beek ER, Lowik CW, Papapoulos SE: Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen containing bisphosphonates on osteoclast precursors. Bone 2002, 30:64-70.
13. Viereck V, Emons G, Lauck V, et al.: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002, 291:680-686. N-BPs at micromolar or lower concentrations produced an increase as much as sevenfold in osteoprotegerin mRNA levels and protein secretion in cultured human osteoblasts. Thus, modulation of osteoprotegerin production by normal human osteoblasts may be another mechanism by which N-BPs inhibit osteoclastic bone resorption.
14. Gowen M, Emery JG, Kumar S: Emerging therapies for osleoporosis. Emerging Drugs 2000, 5:1-43.
15. Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
16. Yasuda H, Shima N, Nakagawa N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95:3597-3602.
17. Morony S, Capparelli C, Sarosi I, et al.: Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001, 61:4432-4436.
18. Michigami T, Ihara-Watanabe M, Yamazaki M, et al.: Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001, 61:1637-1644.
19. Cruz JC, Alsina M, Craig F, et al.: Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma. Exp Hematol 2001, 29:441-447. Early treatment of mice bearing ARH-77 myeloma cells retarded development of osteolytic lesions and delayed the onset of paraplegia but increased the frequency of macroscopic abdominal tumors.
20. Yaccoby S, Pearse RN, Johnson CL, et al.: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002, 116:278-290. Treatment of severe combined immunodeficient mice bearing human fetal bone implants inoculated with primary human myeloma cells with a bisphosphonate lowered serum levels of human immunoglobulin and increased tumor cell apoptosis, suggesting an antitumor effect. However, because osteoprotegerin treatment resulted in similar changes, this finding appears to be an indirect effect via osteoclast inhibition.
21. Holen I, Croucher PI, Hamdy FC, et al.: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002, 62:1619-1623.
22. Senaratne SG, Pirianov G, Mansi JL, et al.: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82:1459-1468.
23. Diel IJ, Solomayer EF, Costa SD, et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357-363.
24. Kanis JA, Powles T, Paterson AH, et al.: Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19:663-667.
25. Saarto T, Blomqvist C, Virkkunen P, et al.: Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-Year results of a randomized controlled trial. J Clin Oncol 2001, 19:10-17.
26. Diel IJ: Antitumor effects of bisphosphonates: First evidence and possible mechanisms. Drugs 2000, 59:391-399.
27. Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998, 16:593-602.
28. Lipton A, Theriault RL, Hortobagyi GN, et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082-1090.
29. McCloskey EV, Dunn JA, Kanis JA, et al.: Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol 2001, 113:1035-1043.
30. Aparicio A, Gardner A, Tu Y, et al.: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998, 12:220-229.
31. Derenne S, Amiot M, Barille S, et al.: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999, 14:2048-2056.
32. Hiraga T, Williams PJ, Mundy GR, et al.: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 2001, 61:4418-4424. Ibandronate treatment of nude mice inoculated with MDA-231 breast cancer ceils increased apoptosis of tumor cells and osteoclasts in bone metastases, and tumor burden was also significantly decreased. These data suggest that the proapoptotic effects of bisphosphonates are restricted to bone, where these compounds selectively accumulate.
33. Lee MV, Fong EM, Singer FR, et al.: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001, 61:2602-2608.
34. Mackie PS, Fisher JL, Zhou H, et al.: Bisphosphonates regutate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 2001, 84:951-958.
35. Shipman CM, Rogers MJ, Apperley JF, et al.: Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumor activity. Br J Haematol 1997, 98:665-672.
36. Shipman CM, Croucher PI, Russell RG, et al.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58:5294-5297.
37. Sonnemann J, Eckervogt V, Truckenbrod B, et al.: The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001, 12:459-465.
38. Takahashi R, Shimazaki C, Inaba T, et al.: A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001, 25:77-83.
39. Tassone P, Tagliaferri P, Galea E: Growth inhibition and apoptosis are induced by zoledronic acid on human pancreatic cell lines. Proc Am Assoc Cancer Res 2000, 43:956-957.
40. Sato M, Grasser W, Endo N, et al.: Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
41. Senaratne SG, Oades GM, Pickering LM, et al.: The bisphosphonate zoledronic acid induces apoptosis by impairing ras membrane localisation and inducing cytochrome c release in breast and prostate cancer cells. Proc Am Assoc Cancer Res 2002, 43:871.
42. Oades GM, Kirby RS, Senaratne S, et al.: Bisphosphonate Induced Apoptosis in Prostate Cancer Cells in Caspase Dependent and Initiated by Inhibition of the Mevalonate Pathway. Available at: http://aua02.agora.com/planner/displayabtract.asp?presentationid=2921. Accessed May 24, 2002.
43. Jagdev SP, Coleman RE, Shipman CM, et al.: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001, 84:1126-1134. Treatment of breast cancer cells with zoledronic acid in combination with paclitaxel resulted in a fourfold to fivefold increase in tumor cell apoptosis compared with either agent alone, and isobologram analysis confirmed a true synergistic interaction between the two drugs.
44. Tassone P, Forciniti S, Galea E, et al.: Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 2000, 14:841-844.
45. Croucher P, De Raeve H, Perry M, et al.: Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma. Bone 2002, 30(suppl):39S.
46. Peyruchaud O, Winding B, Pecheur I, et al.: Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: Application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001, 16:2027-2034. Use of an in vivo fluorescent imaging technique demonstrated that zoledronic acid decreases bone tumor mass in nude mice injected with a human breast cancer cell line.
47. Nobuyuki H, Hiraga T, Williams PJ, et al.: The bisphosphonate zoledronic acid inhibits metastases to bone and liver with suppression of osteopontin production in mouse mammary tumor. J Bone Miner Res 2001, 16(suppl 1):S191.
48. Alvarez E, Galbreath EJ, Westmore M, et al.: Properties of bisphosphonates in the 13762 syngeneic rat mammary carcinoma model of tumor induced bone resorption. Proc Am Assoc Cancer Res 2002, 43:316.
49. Corey E, Quinn JE, Brown LG, et al.: Examination of effects of zoledronic acid on prostate cancer. J Bone Miner Res 2001, 1(suppl 1):S192.
50. Green JR, Gschaidmeier H, Yoneda T, et al.: Zoledronic acid potently inhibits tumor-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol 2000, 11(suppl 4):14.
51. Boissier S, Magnetto S, Frappart L, et al.: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997, 57:3890-3894.
52. van der Pluijm G, Vloedgraven H, van Beek E, et al.: Bisphosphonates inhibit the adhesion of breast cancer ceils to bone matrices in vitro. J Clin Invest 1996, 98:698-705.
53. Boissier S, Ferreras M, Peyruchaud O, et al.: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60:2949-2954.
54. Virtanen SS, Väänänen HK, Härkönen PL, et al.: Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002, 62:2708-2714. Extensive in vitro studies of the effects of alendronate on prostate cancer cells have demonstrated the importance of the mevalonate pathway for tumor cell invasion, migration, and adhesion.
55. Pritchard SC, Nicolson MC, Lloret C, et al.: Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: Implications for MMP inhibition therapy. Oncol Rep 2001, 8:421-424.
56. Costa L, Fernandes A, Frauenhoffer E, et al.: The expression of matrix metalloproteinases (MMPs) in bone metastases is independent of primary tumor and is increased in patients treated with bisphosphonates. Proc Am Soc Clin Oncol 2002, 21:449a.
57. Wood J, Bonjean K, Ruetz S, et al.: Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J Pharm Exp Ther 2002, 302:1055-1061. The first publication reporting angiostatic effects of N-BPs in vitro and in vivo.
58. Bonjean K, Bellahcene A, Locigno R, et al.: Zoledronate modulates endothelial cell surface receptors involved in angiogenesis. Proc Am Assoc Cancer Res 2001, 42:106.
59. Boissier S, Colombel M, Delmas P, et al.: Zoledronic acid inhibits in vivo experimental angiogenesis. Bone 2002, 30(suppl 3):S38.
60. Cuenca AG, Cheng FD, Wang HW, et al.: Modulation of antigen-presenting cells (APCs) function by aminobisphosphonates enhances T-cell priming and prevents tumor-induced T-cell tolerance. Blood 2001, 98:235a.
61. Pecherstorfer M, Jilch R, Sauty A, et al.: Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 2000, 15:147-154.
62. Sansoni P, Passeri G, Fagnoni F, et al.: Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995, 10:1719-1725.
63. Kunzmann V, Bauer E, Feurle J, et al.: Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000, 96:384-392.
64. Das H, Wang L, Kamath A, et al.: Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 2001, 98:1616-1618.
65. Baker J, Verneris MR, Kivivuori SM, et al.: Bisphosphonate and IPP expanded γ δT cells have in vitro and in vivo antitumor function. Blood 2001, 98:167a.